canrenone has been researched along with Chronic Disease in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (40.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boccanelli, A; Cacciatore, G; Clemenza, F; de Simone, G; Di Lenarda, A; Gavazzi, A; Latini, R; Lucci, D; Maggioni, AP; Masson, S; Mureddu, GF; Porcu, M; Vanasia, M | 1 |
| Chen, YQ; Deng, SB; Du, JL; Hu, LJ; She, Q | 1 |
| Abosehmah-Albidy, AZ; Chrystyn, H; Losowsky, MS; Wong, V; York, P | 1 |
| Branch, R; Jackson, L; Levine, D; Ramsay, L | 1 |
| Andriulli, A; Armanini, D; Arrigoni, A; Buzzetti, G; Gindro, T; Karbowiak, I | 1 |
1 review(s) available for canrenone and Chronic Disease
| Article | Year |
|---|---|
Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis.
Topics: Canrenone; Chronic Disease; Eplerenone; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Severity of Illness Index; Spironolactone; Ventricular Remodeling | 2013 |
3 trial(s) available for canrenone and Chronic Disease
| Article | Year |
|---|---|
Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Canrenone; Chronic Disease; Creatinine; Double-Blind Method; Female; Heart Failure; Humans; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Natriuretic Peptide, Brain; Treatment Outcome; Ultrasonography; Ventricular Remodeling; Young Adult | 2009 |
Improved bioavailability and clinical response in patients with chronic liver disease following the administration of a spironolactone: beta-cyclodextrin complex.
Topics: beta-Cyclodextrins; Biological Availability; Canrenone; Chronic Disease; Cross-Over Studies; Cyclodextrins; Diuresis; Diuretics; Female; Humans; Liver Diseases; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Spironolactone; Treatment Outcome; Water-Electrolyte Balance | 1997 |
Canrenone and androgen receptor-active materials in plasma of cirrhotic patients during long-term K-canrenoate or spironolactone therapy.
Topics: Adult; Aged; Ascites; Canrenoic Acid; Canrenone; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Male; Middle Aged; Pregnadienes; Random Allocation; Receptors, Androgen; Recurrence; Spironolactone; Testosterone; Time Factors | 1989 |
1 other study(ies) available for canrenone and Chronic Disease
| Article | Year |
|---|---|
Elimination of canrenone in congestive heart failure and chronic liver disease.
Topics: Aged; Canrenone; Chronic Disease; Creatinine; Female; Half-Life; Heart Failure; Humans; Liver Diseases; Male; Middle Aged; Pregnadienes; Serum Albumin; Spironolactone | 1977 |